Search

• GSK and Sanofi announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of phase III trial per independent Monitoring Board recommendation

  Media

  Companies intend to file booster data with regulatory authorities following the phase III results

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-sanofi-announce-positive-preliminary-booster-data-for-their-covid-19-vaccine-candidate/

  First published: 15 December 2021

• US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults

  Media

  Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time

  https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/

  First published: 03 May 2023

• European Commission authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults

  Media

  Authorisation will help protect adults 60 years of age and older in 30 European countries from RSV disease for the first time

  https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/

  First published: 07 June 2023

• Pandemic (H1N1) 2009 Influenza Update: Results from second clinical trial of GSK’s H1N1 adjuvanted vaccine confirm immune response and tolerability

  Media

  GSK announced results from a second clinical trial of its pandemic (H1N1) adjuvanted vaccine.

  https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-results-from-second-clinical-trial-of-gsk-s-h1n1-adjuvanted-vaccine-confirm-immune-response-and-tolerability/

  First published: 15 October 2009

• Pandemic 2009 Influenza Update: Pandemrix™ data in an elderly population

  Media

  GlaxoSmithKline (GSK) today announced that this week, approximately half a million people will have received its pandemic H1N1 vaccine.

  https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-pandemrix-data-in-an-elderly-population/

  First published: 27 October 2009

• European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk

  Media

  Authorisation helps protect this population for the first time ahead of this RSV season

  https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-expanded-age-indication-for-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-adults-aged-50-59-at-increased-risk/

  First published: 29 August 2024

• Medicines and Healthcare products Regulatory Agency authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults

  Media

  Authorisation will help protect adults 60 years of age and older in the UK from RSV disease for the first time

  https://www.gsk.com/en-gb/media/press-releases/medicines-and-healthcare-products-regulatory-agency-authorises-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/

  First published: 10 July 2023

• US Department of Health and Human Services (HHS) purchases GSK’s A (H1N1) influenza antigen and proprietary adjuvant system

  Media

  GSK announced HHS has placed initial orders for H1N1 vaccine antigen and proprietary adjuvant system, AS03.

  https://www.gsk.com/en-gb/media/press-releases/us-department-of-health-and-human-services-hhs-purchases-gsk-s-a-h1n1-influenza-antigen-and-proprietary-adjuvant-system/

  First published: 21 May 2009

• GSK presents new data for shingles candidate vaccine at IDWeek scientific conference

  Media

  GSK today announced new data for its shingles candidate vaccine ShingrixTM.

  https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-for-shingles-candidate-vaccine-at-idweek-scientific-conference/

  First published: 27 October 2016

• Pandemic 2009 Influenza Update: Pandemrix™ data in children and adolescents from 3 to 17 years of age

  Media

  GlaxoSmithKline (GSK) today announced that over 40 million doses of its adjuvanted pandemic H1N1 vaccine have been distributed to countries.

  https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-pandemrix-data-in-children-and-adolescents-from-3-to-17-years-of-age/

  First published: 22 November 2009